The incidence and prevalence of heart failure with preserved ejection fraction (HFpEF)
continue to rise in tandem with the increasing age and burdens of obesity, sedentariness …

The heart failure syndrome has first been described as an emerging epidemic about 25
years ago. Today, because of a growing and ageing population, the total number of heart …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …

Obesity and heart failure with preserved ejection fraction (HFpEF) represent two
intermingling epidemics driving perhaps the greatest unmet health problem in …

Objectives The goal of this study was to evaluate the effect of empagliflozin, in addition to
optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis …

The prevalence of cardiometabolic disorders in both women and men has increased
worldwide and is linked to a rise in obesity and obesity-associated associated clustering of …

Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome associated
with poor quality of life, substantial health-care resource utilization, and premature mortality …

Heart failure (HF) is the most rapidly growing cardiovascular health burden worldwide. HF
can be classified into three groups based on the percentage of the ejection fraction (EF) …

Objectives: This study evaluated the associations of obesity and cardiometabolic traits with
incident heart failure with preserved versus reduced ejection fraction (HFpEF vs. HFrEF) …